主动监测中前列腺MRI的PRECISE评分标准化解读
本文综述PRECISE评分在前列腺癌主动监测连续MRI评估中的应用。PRECISE为间隔变化提供结构化分级,弥补PI-RADS仅用于病灶检出而不适合纵向比较的不足。证据显示其排除临床显著进展的阴性预测值较高,但阳性预测值有限。
要点
- PRECISE用于标准化评估连续前列腺MRI的间隔变化,分为退缩、稳定与进展。
- PRECISE更适合作排除工具,对临床显著进展具有较高阴性预测值。
- 阅片时需结合PSA动力学、活检结果和临床背景,不能单独依赖MRI。
核心结论
- PRECISE评分系统为前列腺癌主动监测提供结构化的连续MRI间隔变化评估框架。
- 现有证据表明PRECISE排除临床显著进展的阴性预测值持续较高。
- 影像学进展对组织病理升级的阳性预测值较为有限。
研究设计与样本
- 本文为实用综述,未报告原始研究样本量、中心数、设备或序列参数。
- 综述围绕PRECISE及PRECISE version 2的定义、证据基础与临床应用展开。
关键影像表现/征象
- PRECISE version 2区分为稳定可见病灶与稳定不可见病灶。
- PRECISE version 2纳入非诊断性检查的识别。
诊断标准与关键数值
- PRECISE将连续MRI间隔变化分为影像学退缩、稳定和进展类别。
- PRECISE version 2进一步细化定义并设置更清晰的分类标准。
- PRECISE的阴性预测值较高,阳性预测值对组织病理升级有限。
临床应用与阅片要点
- 在主动监测连续MRI报告中应使用PRECISE评估间隔变化,减少主观判断。
- 阅片时应结合PSA动力学、活检结果与临床背景综合解释连续MRI。
- 注意MRI质量差异和主动监测方案异质性可能影响PRECISE应用。
局限性
- PRECISE应用受MRI质量差异和主动监测方案异质性的影响。
- 影像学进展对组织病理升级的阳性预测值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Active surveillance (AS) is an established management strategy for men with low-risk and some favorable intermediate-risk prostate cancer. Multiparametric MRI (MRI) plays an increasingly important role in AS, contributing to initial risk stratification, confirmatory evaluation, and longitudinal monitoring. However, comparing baseline and follow-up MR images is challenging because acquisition varies, readers differ, and imaging alone has limited ability to define clinically meaningful progression. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system was developed to standardize the assessment of interval change on serial prostate MRI. PRECISE provides a structured framework for categorizing radiologic regression, stability, and progression, thereby addressing a key limitation of Prostate Imaging - Reporting and Data System (PI-RADS), which was designed for lesion detection rather than longitudinal assessment. PRECISE version 2 further refines definitions and introduces clearer categories, including separation of stable visible and stable non-visible disease and recognition of non-diagnostic examinations. Available evidence suggests that PRECISE performs best as a rule-out tool, with consistently high negative predictive value for clinically significant progression, while radiologic progression demonstrates more limited positive predictive value for histopathologic upgrading. Although PRECISE reduces subjective interpretation through structured scoring, its application remains affected by variability in MRI quality and heterogeneity in AS protocols. To mitigate these limitations, radiologists should incorporate prostate-specific antigen kinetics, biopsy results, and clinical context into their interpretation of serial MRI. In this review, we provide a practical, radiologist-focused overview of PRECISE, summarize its evolution and evidence base, and illustrate its application in clinical practice. We also discuss key limitations, common pitfalls, and the importance of MRI quality and standardization in improving reproducibility. PRECISE represents an important step toward standardized longitudinal assessment in prostate cancer AS and supports more consistent, evidence-based multidisciplinary decision-making.
引用
- Firoozeh, Ahn, Baroni, et al. Standardizing serial prostate MRI in active surveillance: a practical review of PRECISE scoring. Abdom Radiol (NY). 2026. PMID: 42541554. doi:10.1007/s00261-026-05702-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。